|
Volumn 62, Issue 6, 2000, Pages 681-685
|
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218
a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CHIKUNGUNYA FEVER VACCINE;
LIVE VACCINE;
NEUTRALIZING ANTIBODY;
PLACEBO;
TSI GSD 218;
UNCLASSIFIED DRUG;
VIRUS VACCINE;
ANTIBODY PRODUCTION;
ARTHRALGIA;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DENGUE;
DISEASE SEVERITY;
DOUBLE BLIND PROCEDURE;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HUMAN;
HUMAN EXPERIMENT;
IMMUNIZATION;
IMMUNOGENICITY;
INFLUENZA;
MALE;
NORMAL HUMAN;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
URTICARIA;
CHIKUNGUNYA VIRUS;
RNA VIRUSES;
|
EID: 0034457916
PISSN: 00029637
EISSN: None
Source Type: Journal
DOI: 10.4269/ajtmh.2000.62.681 Document Type: Article |
Times cited : (273)
|
References (30)
|